The Pharamron-backed oncology drug developer floated at the top of its range while increasing the number of shares in the offering.

Lilly Asia Ventures and Johnson & Johnson Innovation – JJDC are both investing in a series A round for the cell therapy developer, a spinoff from Genscript Biotech.

The UCL and Ludwig Institute for Cancer Research spinout has collected $125m from investors including existing shareholder Vives Louvain Technology Fund.

Undisclosed pharmaceutical companies were among the investors in the venture firm's third fund, which will target biopharmaceutical developers.

Posco Capital was among the participants as Cytovant, an Asia-focused spinoff from Roivant Sciences, secured $23.5m a year after it was launched.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Perceptive Advisors led a $55m round for Ionis-backed rare disease drug developer Dynacure following a 2018 round that was the same size.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Corporate venturing unit Amgen Ventures contributed to a $25.5m funding round for the microfluidics healthcare technology developer.

Cowen and European Investment Bank added $52m to a $130m first tranche closed by the AbbVie and Pfizer-backed kidney injury drug developer in July.